Novo Nordisk A/S $NVO Shares Bought by Curi RMB Capital LLC

Key Points

• Curi RMB Capital LLC significantly increased its stake in Novo Nordisk A/S by 339.7% in the first quarter, acquiring a total of 51,146 shares valued at approximately $3.6 million.
• Novo Nordisk's stock is currently down 1.0%, with a market cap of $250.71 billion and an earnings per share (EPS) of $0.97 for the last quarter, surpassing expectations.
• The company announced a semi-annual dividend of $0.4119, yielding 240%, while also experiencing recent downgrades in stock ratings from multiple analysts.

Curi RMB Capital LLC raised its position in Novo Nordisk A/S (NYSE:NVO - Free Report) by 339.7% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 51,146 shares of the company's stock after buying an additional 39,514 shares during the period. Curi RMB Capital LLC's holdings in Novo Nordisk A/S were worth $3,597,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the company. Xponance Inc. boosted its holdings in Novo Nordisk A/S by 5.0% in the 1st quarter. Xponance Inc. now owns 3,314 shares of the company's stock worth $230,000 after buying an additional 158 shares during the last quarter. Foster Dykema Cabot & Partners LLC boosted its holdings in Novo Nordisk A/S by 3.8% in the 1st quarter. Foster Dykema Cabot & Partners LLC now owns 4,526 shares of the company's stock worth $319,000 after buying an additional 166 shares during the last quarter. 180 Wealth Advisors LLC boosted its holdings in Novo Nordisk A/S by 3.6% in the 1st quarter. 180 Wealth Advisors LLC now owns 5,014 shares of the company's stock worth $348,000 after buying an additional 173 shares during the last quarter. LRI Investments LLC boosted its holdings in Novo Nordisk A/S by 1.4% in the 4th quarter. LRI Investments LLC now owns 13,060 shares of the company's stock worth $1,123,000 after buying an additional 176 shares during the last quarter. Finally, Beacon Financial Group boosted its holdings in Novo Nordisk A/S by 6.5% in the 1st quarter. Beacon Financial Group now owns 2,884 shares of the company's stock worth $200,000 after buying an additional 177 shares during the last quarter. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Novo Nordisk A/S Stock Down 1.0%

NVO stock opened at $56.15 on Friday. The firm has a market cap of $250.71 billion, a PE ratio of 15.43, a PEG ratio of 1.97 and a beta of 0.66. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.56 and a current ratio of 0.78. The firm's 50 day moving average price is $59.72 and its 200-day moving average price is $67.81. Novo Nordisk A/S has a one year low of $45.05 and a one year high of $138.22.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last posted its earnings results on Wednesday, August 6th. The company reported $0.97 earnings per share for the quarter, beating the consensus estimate of $0.93 by $0.04. Novo Nordisk A/S had a net margin of 35.60% and a return on equity of 78.64%. The firm had revenue of $11.69 billion during the quarter, compared to the consensus estimate of $77.51 billion. On average, equities research analysts anticipate that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Cuts Dividend

The business also recently announced a semi-annual dividend, which was paid on Tuesday, August 26th. Investors of record on Monday, August 18th were issued a $0.4119 dividend. This represents a yield of 240.0%. The ex-dividend date was Monday, August 18th. Novo Nordisk A/S's dividend payout ratio (DPR) is 22.53%.

Analysts Set New Price Targets

A number of research firms have weighed in on NVO. Wall Street Zen lowered shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research note on Saturday, August 2nd. HSBC lowered shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating and set a $57.00 target price on the stock. in a research note on Thursday, July 31st. Zacks Research lowered shares of Novo Nordisk A/S from a "hold" rating to a "strong sell" rating in a research note on Wednesday, August 20th. TD Cowen decreased their target price on shares of Novo Nordisk A/S from $105.00 to $70.00 and set a "buy" rating on the stock in a research note on Tuesday, August 19th. Finally, BNP Paribas raised shares of Novo Nordisk A/S from an "underperform" rating to a "neutral" rating in a research note on Wednesday, August 13th. Three equities research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and an average target price of $81.00.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.